<DOC>
	<DOCNO>NCT01859741</DOCNO>
	<brief_summary>The study consist Phase1b lead-in portion determine MTD OMP-59R5 combination EP 6 cycle follow Phase 2 , multicenter , randomize , placebo-controlled portion compare efficacy safety OMP-59R5 combination EP 6 cycle follow single agent OMP-59R5 relative EP alone 6 cycle subject receive first-line therapy extensive stage small cell lung cancer .</brief_summary>
	<brief_title>A Phase 1b/2 Study OMP-59R5 Combination With Etoposide Platinum Therapy Subjects With Untreated Extensive Stage Small Cell Lung Cancer ( PINNACLE )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Subjects must meet follow criterion eligible study : 1 . Histologically cytologically document extensive stage small cell lung cancer . 2 . Adults 18 year age old . 3 . Performance Status ( ECOG ) 0 1 . 4 . FFPE tumor tissue . 5 . Adequate organ function : 1 . Adequate hematologic function ( absolute neutrophil count [ ANC ] ≥ 1,500 cells/μL ; hemoglobin ≥ 9 g/dL , platelet ≥ 100,000/μL ) . 2 . Adequate renal function ( serum creatinine ≤ 1.5 mg/dL calculate creatinine clearance ≥ 60 mL/min use CockcroftGault formula ) . 3 . Adequate hepatic function ( alanine aminotransferase [ ALT ] ≤ 3 x upper limit normal [ ULN ] , ALT may ≤ 5 x ULN due liver metastasis associate concurrent elevate bilirubin &gt; 1.5xULN unless approve Sponsor 's Medical Monitor ) . 4 . Prothrombin Time ( PT ) /International Normalized Ration ( INR ) ≤1.5 × ULN , activate partial thromboplastin time ( aPTT ) ≤1.5 × ULN . 6 . Written consent IRB/IECapproved Informed Consent Form prior studyspecific evaluation . 7 . For woman childbearing potential , negative serum pregnancy test screening use physicianapproved method birth control 30 day prior first study drug administration 30 day follow last study drug administration last EP study , whichever discontinue last . 8 . Male subject must surgically sterile must agree use physicianapproved contraception study 30 day follow last study drug administration last EP study , whichever discontinue last . Subjects meet follow criterion eligible participation study : 1 . Limited stage small cell lung cancer appropriate radical treatment chemoradiation . 2 . Prior therapy include radiation , chemotherapy surgery newly diagnose extensive stage small cell lung cancer . 3 . Presence serious uncontrolled illness include , limited : ongoing active infection , symptomatic congestive heart failure unstable angina pectoris , uncontrolled cardiac arrhythmia , uncontrolled arterial thrombosis , symptomatic pulmonary embolism , psychiatric illness would limit compliance study requirement . 4 . History myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty and/or stenting within 6 month prior first administration study drug . 5 . A history malignancy exception : 1 . Adequately treat basal cell carcinoma , squamous cell carcinoma skin , situ cervical cancer 2 . Adequately treated stage I cancer subject currently remission , 3 . Any cancer subject diseasefree ≥ 3 year 6 . Known human immunodeficiency virus ( HIV ) infection . 7 . Females pregnant breastfeeding . 8 . Concurrent use therapeutic warfarin ( prophylactic low dose warfarin , i.e. , 1 mg daily port catheter allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Newly diagnose Stage IV Small Cell Lung Cancer</keyword>
</DOC>